|Dr. Yaping Hong Ph.D.||Sr. VP of Global Process R&D||N/A||N/A||61|
|Mr. Mark D. Dacko||Controller and Assistant Sec.||N/A||N/A||66|
|Dr. Michael Cannarsa Ph.D.||Gen. Mang. of Chiral Quest||N/A||N/A||60|
|Dr. Lawrence Akinsanmi M.D., Ph.D.||VP of Clinical Operations & Regulatory Affairs||N/A||N/A||N/A|
|Dr. Vernon L. Alvarez Ph.D.||VP of R&D||N/A||N/A||N/A|
VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The companys products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.
VioQuest Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.